NasdaqGM:TBPH

Stock Analysis Report

Executive Summary

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines.

Snowflake

Fundamentals

High growth potential with mediocre balance sheet.

Risks

  • Theravance Biopharma has significant price volatility in the past 3 months.

Share Price & News

How has Theravance Biopharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

1.7%

NasdaqGM:TBPH

-0.5%

US Pharmaceuticals

0.5%

US Market


1 Year Return

-32.8%

NasdaqGM:TBPH

6.0%

US Pharmaceuticals

0.8%

US Market

TBPH underperformed the Pharmaceuticals industry which returned 6% over the past year.

TBPH underperformed the Market in United States of America which returned 0.8% over the past year.


Share holder returns

TBPHIndustryMarket
7 Day1.7%-0.5%0.5%
30 Day-22.6%0.007%-0.06%
90 Day-33.8%-2.9%1.0%
1 Year-32.8%-32.8%8.5%6.0%3.0%0.8%
3 Year-26.9%-26.9%17.3%9.1%47.3%37.5%
5 Year-53.6%-53.6%27.8%14.0%54.7%37.5%

Price Volatility Vs. Market

How volatile is Theravance Biopharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Theravance Biopharma undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Theravance Biopharma's share price is below the future cash flow value, and at a moderate discount (> 20%).

Theravance Biopharma's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Theravance Biopharma is loss making, we can't compare its value to the US Pharmaceuticals industry average.

Theravance Biopharma is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Theravance Biopharma, we can't assess if its growth is good value.


Price Based on Value of Assets

Theravance Biopharma has negative assets, we can't compare the value of its assets to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Theravance Biopharma expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

40.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Theravance Biopharma's revenue is expected to grow significantly at over 20% yearly.

Theravance Biopharma's earnings are expected to grow significantly at over 20% yearly.

Theravance Biopharma's revenue growth is expected to exceed the United States of America market average.

Theravance Biopharma's earnings growth is expected to exceed the United States of America market average.

Theravance Biopharma's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Theravance Biopharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Theravance Biopharma performed over the past 5 years?

-5.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Theravance Biopharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Theravance Biopharma's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Theravance Biopharma's 1-year growth to the US Pharmaceuticals industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Theravance Biopharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if Theravance Biopharma has efficiently used its assets last year compared to the US Pharmaceuticals industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Theravance Biopharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

  • Explore strong past performing companies in the pharmaceuticals & biotech industry.

Financial Health

How is Theravance Biopharma's financial position?


Financial Position Analysis

Theravance Biopharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Theravance Biopharma's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

Theravance Biopharma has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if Theravance Biopharma's debt level has increased considering it has negative shareholder equity.


Balance Sheet

Low level of unsold assets.

Theravance Biopharma has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Theravance Biopharma has sufficient cash runway for 1.8 years based on current free cash flow.

Theravance Biopharma has sufficient cash runway for 1.7 years if free cash flow continues to grow at historical rates of 11.3% each year.


Next Steps

Dividend

What is Theravance Biopharma's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Theravance Biopharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Theravance Biopharma's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Theravance Biopharma has not reported any payouts.

Unable to verify if Theravance Biopharma's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Theravance Biopharma has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Theravance Biopharma's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

  • Explore strong dividend paying companies in the pharmaceuticals & biotech industry.

Management

What is the CEO of Theravance Biopharma's salary, the management and board of directors tenure and is there insider trading?

3.3yrs

Average management tenure


CEO

Rick Winningham (58yo)

5.0yrs

Tenure

US$2,522,841

Compensation

Mr. Rick E. Winningham has been the Chairman and Chief Executive Officer at Theravance Biopharma, Inc. since its spin-off from Theravance, Inc. since July 2013 and since June 2014 respectively. Mr. Winning ...


CEO Compensation Analysis

Rick's remuneration is about average for companies of similar size in United States of America.

Rick's compensation has increased whilst company is loss making.


Management Age and Tenure

3.3yrs

Average Tenure

56yo

Average Age

The tenure for the Theravance Biopharma management team is about average.


Board Age and Tenure

5.4yrs

Average Tenure

66.5yo

Average Age

The tenure for the Theravance Biopharma board of directors is about average.


Insider Trading

Theravance Biopharma insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$81,83520 May 19
Donal O'Connor
EntityIndividual
Role
Member of the Board of Directors
Shares4,000
Max PriceUS$21.00
SellUS$223,16907 Mar 19
Sharathchandra Hegde
EntityIndividual
Role
Senior Vice President of Research
Shares9,033
Max PriceUS$25.06
SellUS$182,20114 Sep 18
Phillip Worboys
EntityIndividual
Shares6,393
Max PriceUS$28.50
SellUS$197,28229 Aug 18
Bradford Shafer
EntityIndividual
Role
Executive VP
Shares7,119
Max PriceUS$27.71
SellUS$1,171,79116 Aug 18
Reneé Galá
EntityIndividual
Shares43,743
Max PriceUS$27.74
SellUS$874,57509 Aug 18
Bradford Shafer
EntityIndividual
Role
Executive VP
Shares31,300
Max PriceUS$28.99

Ownership Breakdown


Management Team

  • Sharath Hegde (54yo)

    Senior Vice President of Research

    • Tenure: 3.3yrs
    • Compensation: $2.40m
  • Bradford Shafer (58yo)

    Executive VP

    • Tenure: 4.8yrs
    • Compensation: $1.12m
  • Rhonda Farnum

    Vice President of Sales & Marketing

    • Tenure: 0.9yrs
  • Brett Haumann (48yo)

    Senior VP of Clinical Development & Chief Medical Officer

    • Tenure: 4.5yrs
    • Compensation: $1.52m
  • Vijay Sabesan

    Senior Vice President of Technical Operations

    • Tenure: 1.8yrs
  • Andrew Hindman (45yo)

    Senior VP & CFO

  • Rick Winningham (58yo)

    Chairman & CEO

    • Tenure: 5.0yrs
    • Compensation: $2.52m
  • Dennis Driver

    Senior VP of Human Resources

    • Tenure: 3.3yrs
  • Frank Pasqualone (62yo)

    Senior VP & Chief Commercial Operations Officer

    • Tenure: 3.3yrs
    • Compensation: $906.26k
  • Alex Dobbin

    Head of Investor Relations


Board Members

  • Bob Gunderson (66yo)

    Director

    • Tenure: 5.7yrs
    • Compensation: $341.87k
  • Susan Molineaux (64yo)

    Director

    • Tenure: 4.2yrs
    • Compensation: $356.67k
  • Eran Broshy (59yo)

    Director

    • Tenure: 5.0yrs
    • Compensation: $364.87k
  • Donal O'Connor (67yo)

    Director

    • Tenure: 3.7yrs
    • Compensation: $361.37k
  • Burt Malkiel (85yo)

    Director

    • Tenure: 5.7yrs
    • Compensation: $385.87k
  • Bill Young (73yo)

    Lead Independent Director

    • Tenure: 5.2yrs
    • Compensation: $391.87k
  • George Whitesides (79yo)

    Director

    • Tenure: 5.7yrs
    • Compensation: $353.87k
  • Peter Ringrose (72yo)

    Director

    • Tenure: 5.7yrs
    • Compensation: $365.87k
  • Dean Mitchell (62yo)

    Director

    • Tenure: 5.0yrs
    • Compensation: $360.87k
  • Rick Winningham (58yo)

    Chairman & CEO

    • Tenure: 5.9yrs
    • Compensation: $2.52m

Company Information

Theravance Biopharma, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Theravance Biopharma, Inc.
  • Ticker: TBPH
  • Exchange: NasdaqGM
  • Founded: 2013
  • Industry: pharmaceuticals
  • Sector: pharmaceuticals & biotech
  • Market Cap: US$895.388m
  • Shares outstanding: 56.14m
  • Website: Click here

Number of Employees


Location

  • Theravance Biopharma, Inc.
  • Ugland House
  • South Church Street
  • George Town
  • KY1-1104
  • Cayman Islands

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TBPHNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDJan 1970
0TBDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 1970

Biography

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable ant ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/06/16 00:44
End of Day Share Price2019/06/14 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.